biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Post by OysterBuctoucheon Sep 12, 2019 9:32am

134 Views

Post# 30119359

China Japan Patents

The announcements of patent allowance in both China and Japan have not received much in the way of comments on the Board. The complexity and expense of attaining these patents by Bioasis -working with limited resources -must be important for the future of this company. In this light it will be interesting in the next 6 to 12 months to assess other news and deals that may link to these patent allowances. Either Bioasis has a window to this market and it's potential for P97 or partners are helping direct activity as it pertains to potential opportunities and deals. Good work by the Bioasis team and look forward to watching how these markers materialize.

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!